Recently, Marra et al. proved that CD47 expression by IHC varies according to genotype with higher expression in AML patients with favorable risk, especially those with CBFβ/MYH11 and NPM1 mutation [11]. The gene discussed is CBFB; the disease is acute myeloid leukemia.